Banner background image Banner background image

Even with diet and a maximally tolerated statin
MANY PATIENTS WITH
ASCVD STRUGGLE TO
ACHIEVE LDL-C TARGET8-10

Not a real patient.
80% Graphic

do not reach the LDL-C guideline-recommended target of <70 mg/dL11,12

Statins, along with diet and exercise, are often not enough for many patients to reach their recommended target.8-10

Additional treatment options may be
needed to effectively help patients lower
their LDL-C and reach their target.

  • PERSISTENTLY
    ELEVATED
    LDL-C

  • LOW
    STATIN
    TOLERANCE

  • HIGH
    TREATMENT
    BURDEN

Paul is post-event
with persistently
elevated LDL-C

He is a retired mechanic who loves fishing with his grandchildren. He does low-impact exercise a couple of times a week, tries to watch what he eats, and sees his health care provider twice a year.
Paul feels discouraged by the daily demands of his treatment plan, but remains relieved he managed to bring his LDL-C down after his myocardial infarction (MI).

Not a real patient.

He is a retired mechanic who loves fishing with his grandchildren. He does low-impact exercise a couple of times a week, tries to watch what he eats, and sees his health care provider twice a year. Paul feels discouraged by the daily demands of his treatment plan, but remains relieved he managed to bring his LDL-C down after his myocardial infarction (MI).

Age: 65

Insurance: Medicare

LDL-C level: 110 mg/dL

BMI: 36 kg/m2

Currently on maximally
tolerated dose of
atorvastatin (40 mg)

Medical history:

  • CV events: MI 2 years ago, coronary artery bypass surgery (CABG)

  • Additional health conditions: type 2 diabetes and hypertension

Paul's LDL-C reduction since his CV event
Not a real patient.
Paul

June has
persistently
elevated LDL-C
with low statin
tolerance

She is an accountant who enjoys going to local sports games with her family. She sees her health care provider 1-2 times a year, but is not overly worried about her LDL-C and often "cycles" on and off her statin because of side effects. June likes things as they are and doesn't want to increase her daily medications.

Not a real patient.

She is an accountant who enjoys going to local sports games with her family. She sees her health care provider 1-2 times a year, but is not overly worried about her LDL-C and often "cycles" on and off her statin because of side effects. June likes things as they are and doesn't want to increase her daily medications.

Age: 57

Insurance: Commercial
insurance

LDL-C level: 95 mg/dL

BMI: 28 kg/m2

Currently on maximally
tolerated dose of
rosuvastatin (20 mg)

Medical history:

  • CV events: diagnosed 5 years ago with unstable angina, experiences chest pains

  • Additional health conditions: long-standing hypertension, family history of CVD

June's LDL-C reduction since her CV event
Not a real patient.
June

Christine is
post-event with
multiple
comorbidities
and overburdened
by treatment

She is a retired elementary school teacher who lives for visiting her new granddaughter. Though she sees her HCP every 3-6 months, she struggles with adherence and managing her comorbidities and finds it difficult to exercise and eat healthy due to limited time and resources. Christine is overwhelmed by the demands of her current treatment plan and her overall pill burden, while living with the frustration of a lack of treatment success.

Not a real patient.

She is a retired elementary school teacher who lives for visiting her new granddaughter. Though she sees her HCP every 3-6 months, she struggles with adherence and managing her comorbidities and finds it difficult to exercise and eat healthy due to limited time and resources. Christine is overwhelmed by the demands of her current treatment plan and her overall pill burden, while living with the frustration of a lack of treatment success.

Age: 69

Insurance: Medicare

LDL-C level: 140 mg/dL

BMI: 34 kg/m2

Currently on maximally
tolerated dose of atorvastatin
(40 mg) and ezetimibe

Medical history:

  • CV events: heart attack, stent placement 1 year ago

  • Additional health conditions: hypertension, metabolic syndrome, early-stage chronic kidney disease (CKD)

Christine's LDL-C reduction since her CV event
Not a real patient.
Christine

As a complement to a
maximally tolerated statin
and diet, choose LEQVIO®
for
your patients with ASCVD
who have persistently
elevated LDL-C.1


THERE'S MORE TO KNOW ABOUT LEQVIO

See what LEQVIO can do for patients like yours

STUDY CLINICAL DATA arrow

ASCVD, atherosclerotic cardiovascular disease; BMI, body mass index; CV, cardiovascular;
CVD, cardiovascular disease; LDL-C, low-density lipoprotein cholesterol; MI, myocardial infarction.

INDICATION AND IMPORTANT
SAFETY INFORMATION

COLLAPSE

EXPAND

INDICATION

LEQVIO (inclisiran) injection is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with clinical atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) who require additional lowering of low-density lipoprotein cholesterol (LDL-C).

Limitations of Use: The effect of LEQVIO on cardiovascular morbidity and mortality has not been determined.

IMPORTANT SAFETY INFORMATION

Adverse reactions in clinical trials (≥3% of patients treated with LEQVIO and more frequently than placebo) were injection site reaction, arthralgia, urinary tract infection, diarrhea, bronchitis, pain in extremity and dyspnea.

Adverse reactions led to discontinuation in 2.5% and 1.9% of LEQVIO- and placebo-treated patients, respectively. Discontinuation due to injection site reactions, which included injection site pain, erythema and rash, were 0.2% and 0% of LEQVIO- and placebo-treated patients, respectively.

Please click here for LEQVIO full Prescribing Information.

References: 1. LEQVIO [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2021. 2. Cubanski J, Damico A, Neuman T, Jacobson G. Sources of supplemental coverage among Medicare beneficiaries in 2016. KFF. November 28, 2018. Accessed November 5, 2021. https://www.kff.org/medicare/issue-brief/sources-of-supplemental-coverage-among-medicare-beneficiaries-in-2016/# 3. Ray KK, Landmesser U, Leiter LA, et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med. 2017;376(15):1430-1440. doi:10.1056/NEJMoa1615758 4. Data on file. Novartis Pharmaceuticals Corp; 2019. 5. Grundy SM, Stone NJ, Bailey AL, et al. AHN/AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082-e1143. doi:10.1161/CIR.0000000000000625 6. Data on file. Novartis Pharmaceuticals Corp; 2020. 7. Ray KK, Wright RS, Kallend D, et al; ORION-10 and ORION-11 Investigators. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507-1519. doi:10.1056/NEJMoa1912387 8. McClellan M, Brown N, Califf RM, Warner JJ. Call to action: urgent challenges in cardiovascular disease: a presidential advisory from the American Heart Association. Circulation. 2019;139(9):e1-e11. doi:10.1161/CIR.0000000000000652 9. Jacobson T, Cheeley MK, Jones PH, et al. The STatin Adverse Treatment Experience Survey: experience of patients reporting side effects of statin therapy. J Clin Lipidol. 2019;13(6):405-424. 10. Jones PH, Radhika N, Thakker KM. Prevalence of dyslipidemia and lipid goal attainment in statin-treated subjects from 3 data sources: a retrospective analysis. J Am Heart Assoc. 2012;1(6):1-10. doi:10.1161/JAHA.112.001800 11. Fox KM, Tai M-H, Kostev K, Hatz M, Qian Y, Laufs U. Treatment patterns and low-density lipoprotein cholesterol (LDL-C) goal attainment among patients receiving high- or moderate-intensity statins. Clin Res Cardiol. 2018;107(5):380-388. doi:10.1007/s00392-017-1193-z 12. Wong ND, Young D, Zhao Y, et al. Prevalence of the American College of Cardiology/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US adults using the National Health and Nutrition Examination Survey 2011–2012. J Clin Lipidol. 2016;10(5):1109-1118. doi:10.1016/j.jacl.2016.06.011

INDICATION

LEQVIO (inclisiran) injection is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with clinical atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) who require additional lowering of low-density lipoprotein cholesterol (LDL-C).

Limitations of Use: The effect of LEQVIO on cardiovascular morbidity and mortality has not been determined.

IMPORTANT SAFETY INFORMATION

Adverse reactions in clinical trials (≥3% of patients treated with LEQVIO and more frequently than placebo) were injection site reaction, arthralgia, urinary tract infection, diarrhea, bronchitis, pain in extremity and dyspnea.

Adverse reactions led to discontinuation in 2.5% and 1.9% of LEQVIO- and placebo-treated patients, respectively. Discontinuation due to injection site reactions, which included injection site pain, erythema and rash, were 0.2% and 0% of LEQVIO- placebo-treated patients, respectively.

Please click here for LEQVIO full Prescribing Information.

References: 1. LEQVIO [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2021. 2. Cubanski J, Damico A, Neuman T, Jacobson G. Sources of supplemental coverage among Medicare beneficiaries in 2016. KFF. November 28, 2018. Accessed November 5, 2021. https://www.kff.org/medicare/issue-brief/sources-of-supplemental-coverage-among-medicare-beneficiaries-in-2016/# 3. Ray KK, Landmesser U, Leiter LA, et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med. 2017;376(15):1430-1440. doi:10.1056/NEJMoa1615758 4. Data on file. Novartis Pharmaceuticals Corp; 2019. 5. Grundy SM, Stone NJ, Bailey AL, et al. AHN/AHA/ACC/AACVPR/AAPA/ABC/ACPM/
ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082-e1143. doi:10.1161/CIR.0000000000000625 6. Data on file. Novartis Pharmaceuticals Corp; 2020. 7. Ray KK, Wright RS, Kallend D, et al; ORION-10 and ORION-11 Investigators. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507-1519. doi:10.1056/NEJMoa1912387 8. McClellan M, Brown N, Califf RM, Warner JJ. Call to action: urgent challenges in cardiovascular disease: a presidential advisory from the American Heart Association. Circulation. 2019;139(9):e1-e11. doi:10.1161/CIR.0000000000000652 9. Jacobson T, Cheeley MK, Jones PH, et al. The STatin Adverse Treatment Experience Survey: experience of patients reporting side effects of statin therapy. J Clin Lipidol. 2019;13(6):405-424. 10. Jones PH, Radhika N, Thakker KM. Prevalence of dyslipidemia and lipid goal attainment in statin-treated subjects from 3 data sources: a retrospective analysis. J Am Heart Assoc. 2012;1(6):1-10. doi:10.1161/JAHA.112.001800 11. Fox KM, Tai M-H, Kostev K, Hatz M, Qian Y, Laufs U. Treatment patterns and low-density lipoprotein cholesterol (LDL-C) goal attainment among patients receiving high- or moderate-intensity statins. Clin Res Cardiol. 2018;107(5):380-388. doi:10.1007/s00392-017-1193-z 12. Wong ND, Young D, Zhao Y, et al. Prevalence of the American College of Cardiology/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US adults using the National Health and Nutrition Examination Survey 2011–2012. J Clin Lipidol. 2016;10(5):1109-1118. doi:10.1016/j.jacl.2016.06.011